Overview

A Study of Tecogalan Sodium

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

To evaluate the safety of different doses and dosing regimens of tecogalan sodium (DS-4152) and to establish the MTD at each of the different dosing schedules.

Phase:

Phase 1

Details

Lead Sponsor:

Daiichi Pharmaceuticals